Funding roundup: GRAIL raises $390M for cancer liquid biopsy test
GRAIL, a startup developing cancer liquid biopsy tests, raised a $390 million series D round. Read more about which companies raised funding this week.
GRAIL, a startup developing cancer liquid biopsy tests, raised a $390 million series D round. Read more about which companies raised funding this week.